NLRP3 and Hyperglycemia: Blockade of NLRP3 inflammasome–mediated secretion of IL-1β in TET2-deficient immune cells using MCC950 suppressed the higher levels of IL-1β and increased hyperglycemia and IR in mice carrying TET2-deficient HSCs (11).